Switch Therapeutics Company Profile, Contacts & Intelligence

Switch Therapeutics Overview

Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch’s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switch’s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the company’s South San Francisco based team has continued to grow as its research has advanced.

Headquarters

San Francisco, California, United States

Website

switchthera.com

Industry

Biotechnology Research

Founded

2020

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

Switch Therapeutics Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Switch Therapeutics People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Compare Similar Companies to Switch Therapeutics

Explore companies in related markets and compare their industry and employee estimates.